AlphaRx Inc. Initiates Animal Study For Acusolin(TM), A Potential Eye Drop For Cataracts
AlphaRx Inc. (OTC BB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that the development of the formulation for Acusolin™, its 3rd ophthalmic product, has been completed and in vivo studies are underway as scheduled.